Generalisation from phase III clinical trials: survival, quality of life, and health economics

Lancet. 1997 Oct 4;350(9083):1025-7. doi: 10.1016/s0140-6736(97)03053-5.

Authors

P M Fayers¹, D J Hand

Affiliation

¹ Unit for Epidemiology and Clinical Research, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

PMID: 9329528
DOI: 10.1016/s0140-6736(97)03053-5

No abstract available

MeSH terms

Clinical Trials, Phase III as Topic* / economics
Costs and Cost Analysis
Economics, Medical*
Humans
Quality of Life*
Quality-Adjusted Life Years
Randomized Controlled Trials as Topic* / economics
Research Design
Therapeutic Human Experimentation*